New drug combo may make Half-Matched transplants safer for blood cancer patients
NCT ID NCT02996773
First seen Nov 11, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This study tested whether replacing a standard transplant drug (cyclophosphamide) with a different drug (bendamustine) could make half-matched bone marrow transplants safer for people with blood cancers like leukemia and lymphoma. About 50 patients took part. The goal was to reduce side effects like graft-versus-host disease while still controlling the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
Conditions
Explore the condition pages connected to this study.